Helix BioPharma Corp. is seeing a significant rise in its stock price, reflecting investor optimism.
Helix BioPharma Corp. (HBP.TO) is up today, gaining 4.81% to close at CA$1.96. This positive movement comes alongside strategic financial decisions and a focus on advancing its therapeutic programs.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeAdvertisement
Market cap
$142.83M
52W high
$5.40
52W low
$1.10
1W change
+16.88%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 33.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+33.7% Upside
Current Price
C$1.87
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
37.4%
Annualized
90-Day Vol
59.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.24
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.98 | C$1.74 – C$2.26 |
| 60 trading days | C$2.11 | C$1.75 – C$2.53 |
| 90 trading days | C$2.24 | C$1.79 – C$2.80 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors might see Helix BioPharma's recent stock performance as a sign of confidence in the company's future growth, especially as it looks to secure funding for its next phase.
Helix BioPharma Corp. Gains 4.81% in One Day
The stock's increase today brings its market capitalization to CA$142.83 million, indicating strong investor interest in its growth potential.
Bull case
The company recently closed a private placement of convertible debentures, showing a proactive approach to funding. This move could strengthen its ability to push forward critical projects.
Bear case
Despite today's gains, Helix BioPharma's financial situation raises concerns. The company has not reported any profit margins and does not offer dividends, which might discourage some investors.
Recent Developments
Advertisement
Helix BioPharma has successfully closed a private placement of convertible debentures, raising C$3.67 million. This funding is vital for the company's ongoing projects and likely contributed to today's stock price increase.
Market Reaction
The rise in Helix BioPharma's stock price shows a positive market reaction to its recent financial strategies. Investors seem optimistic about the company's ability to secure the necessary funding to advance its therapeutic programs.
Looking Ahead
As Helix BioPharma navigates its financial landscape, investors will be eager to watch for upcoming announcements regarding its financial health and project advancements, especially in the competitive biotechnology sector.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
